Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs

27-03-2024 | Breast Cancer | Research

The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells

Authors: Fatemeh Safari, Setareh Bararpour, Fatemeh Omidi Chomachaei

Published in: Investigational New Drugs

Login to get access

Abstract

Breast cancer is a leading cause of death in women worldwide. Cancer therapy based on stem cells is considered as a novel and promising platform. In the present study, we explore the therapeutic effects of human amniotic mesenchymal stromal cells (hAMSCs) through the reduction of focal adhesion kinase (FAK) activity, SHP-2, and cell adhesion proteins such as Paxillin, Vinculin, Fibronectin, Talin, and integrin αvβ3 expression in MDA-MB-231 breast cancer cells. For this purpose, we employed a co-culture system using 6-well plate transwell. After 72 h, hAMSCs-treated MDA-MB-231 breast cancer cells, the activity of focal adhesion kinase (FAK) and the expression of SHP-2 and cell adhesion proteins such as Paxillin, Vinculin, Fibronectin, Talin, and integrin αvβ3 expression were analyzed using western blot. The shape and migration of cells were also analyzed. Based on our results, a significant reduction in tumor cell motility through downregulation of the tyrosine phosphorylation level of FAK (at Y397 and Y576/577 sites) and cell adhesion expression in MDA-MB-231 breast cancer cells was demonstrated. Our findings indicate that hAMSCS secretome has therapeutic effects on cancer cell migration through downregulation of FAK activity and expression of cell adhesion proteins.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef
2.
3.
Sarukhan A, Zanotti L, Viola A (2015) Mesenchymal stem cells: myths and reality. Swiss Med Wkly 145:w14229PubMed
4.
Tran C, Damaser MS (2015) Stem cells as drug delivery methods: application of stem cell secretome for regeneration. AdvDrug Deliv Rev 82–83:1–11
5.
Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM (2007) Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and proinflammatory factors. J Cell Physiol 212(3):702–709PubMedCrossRef
6.
7.
Sarojini H, Estrada R, Lu H, Dekova S, Lee MJ, Gray RD, Wang E (2008) PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts. J Cell Bioche 104(5):1793–1802CrossRef
8.
Schinkothe T, Bloch W, Schmidt A (2008) In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 17:199–206PubMedCrossRef
9.
Liu CH, Hwang SM (2005) Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32:270–279PubMedCrossRef
10.
Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539–544PubMedCrossRef
11.
12.
Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692:77–102PubMedCrossRef
13.
Calalb MB, Polte RT, Hanks SK (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15:954–963PubMedPubMedCentralCrossRef
14.
Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapde-laine A, Chevalier S (1996) Focal adhesion kinase (pp125) expression, activation and association with paxillin and p50 in human metastatic prostate carcinoma. Int J Cancer 68(2):164–171PubMedCrossRef
15.
Judson PL, He X, Cance WG, Van Le L (1999) Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 86(8):1551–1556PubMedCrossRef
16.
Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, Yang X, Cance WG (2003) Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res 9:215–222PubMed
17.
Owens LV, Xu L, Cravenetal RJ (1995) Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55(13):2752–2755PubMed
18.
Safari F, Murata-Kamiya N, Saito Y, Hatakeyama M (2011) Mammalian pragmin regulates Src family kinases via the glu-pro-ile-tyr-ala (EPIYA) motif that is exploited by bacterial effectors. Proc Natl Acad Sci USA 108:14938–14943PubMedPubMedCentralCrossRef
19.
Tactacan CM, Phua YW, Liu L, Zhang L, Humphrey ES, Cowley M, Pinese M, Biankin AV, Daly RJ (2015) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Mol Cancer 14:139PubMedPubMedCentralCrossRef
20.
21.
Rahmani Z, Safari F (2020) Evaluating the in vitro therapeutic effects of human amniotic mesenchymal stromal cells on MiaPaca2 pancreatic cancer cells using 2D and 3D cell culture model. Tissue Cell 23:101479
22.
Tsutsumi R, Takahashi A, Azuma T, Higashi H, Hatakeyama M (2006) Focal adhesion kinase is a substrate and downstream Effector of SHP-2 complexed with Helicobacter pylori CagA. Mol Cell Biol 26(1):261–276PubMedPubMedCentralCrossRef
23.
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256PubMedCrossRef
24.
Safari F, Shafiee Nejad N, Aghaei Nejad A (2022) The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 signaling. Med Oncol 39:28PubMedCrossRef
25.
Shakery T, Safari F (2023) Downregulation of Pinkbar/pAKT and MMP2/MMP9 expression in MDA-MB-231 breast Cancer cells as potential targets in Cancer Therapy by hAMSCs Secretome. Cells Tissues Organs 212(2):155–163PubMedCrossRef
26.
Biscardi JS, Belsches AP, Parsons SJ (1998) Characterization of human epidermal growth factor receptor and c-Src in human breast tumor cells. Mol Carcinogen 21:261–272CrossRef
27.
Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203–210PubMedPubMedCentralCrossRef
28.
Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-Src oncogene product. Cancer Res 52:4773–4778PubMed
29.
Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G (1996) c-Src protein expression is increased in human breast cancer. An immunohisto-chemical and biochemical analysis. J Pathol 180:383–388PubMedCrossRef
30.
Toi M, Osaki A, Yamada H, Toge T (1991) Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977–980PubMedCrossRef
31.
Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609PubMedCrossRef
32.
Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB, Xu RH (2013) Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis 34:803–811PubMedCrossRef
33.
Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH, Xu RH (2013) Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Translational Medici ne 11:277CrossRef
34.
Hegele A, Heidenreich A, Kropf J, von Knobloch R, Varga Z, Hofmann R, Olbert P (2004) Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumor Biol 25:111–116CrossRef
35.
Saito N, Nishimura H, Kameoka S (2008) Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep 1:77–81PubMed
36.
Wang Y, Kuramitsu Y, Ueno T, Suzuki N, Yoshino S, Iizuka N, Zhang X, Akada J, Oka M, Nakamura K (2012) Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Oncol Rep 28:1845–1850PubMedCrossRef
37.
Kawakami K, Fujita Y, Kato T, Mizutani K, Kameyama K, Tsumoto H, Miura Y, Deguchi T, Ito M (2015) Integrin beta4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane - resis-tance. Int J Oncol 47:384–390PubMedCrossRef
38.
Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M (2008) Patterns of avb3 expression in primary and metastatic human breast Cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 49(2):255–259PubMedCrossRef
39.
Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B (2003) Activated integrin alpha v beta 3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 100:9482–9487PubMedPubMedCentralCrossRef
40.
Liapis H, Flath A, Kitazawa S (1996) Integrin alpha v beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 5:127–135PubMedCrossRef
41.
Desiniotis A, Kyprianou N (2011) Significance of talin in cancer progression and metastasis. Int R ev Cell Mol Biol 289:117–147CrossRef
42.
Sakamoto S, McCann RO, Dhir R, Kyprianou N (2010) Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 70:1885–1895PubMedPubMedCentralCrossRef
43.
Zhang W, Mao YQ, Wang H, Yin WJ, Zhu SX, Wang WC (2015) MiR-124 suppresses cell motility and adhesion by targeting talin 1 in prostate cancer cells. Cancer Cell Int 15:49PubMedPubMedCentralCrossRef
Metadata
Title
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
Authors
Fatemeh Safari
Setareh Bararpour
Fatemeh Omidi Chomachaei
Publication date
27-03-2024
Publisher
Springer US
Published in
Investigational New Drugs
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-024-01434-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits